title: Optimizing the antitumor selectivity of PVP-Hypericin re A549 cancer cells and HLF normal cells through pulsed blue light.
abstract: Photodynamic therapy (PDT) is based on the preferential accumulation of photosensitizer in cancer cells with subsequent cytotoxicity mediated by singlet oxygen production after light excitation. As photosensitizers accumulate also in the surrounding non-cancer cells, the risk of damaging them by photosensitization is a limitation of PDT. Thus, minimizing the side-effects of PDT on normal cells is one of the challenging problems in medical practice. This paper studies the PDT side-effects of PVP-Hypericin (PVP: polyvinylpyrrolidone) photosensitizer excited with continuous or pulsed irradiation, on combined cell lines of human lung carcinoma epithelial cells (A549) and normal primary human lung fibroblast cells (HLF). In vitro PDTs are performed using pulsed or continuous irradiation with irradiance intensities I(*)=1.59, 6.34 and 14.27 mW/cm(2). The LED pulse lengths L are 0.127, 1.29, 13, 54.5 and 131 ms. Then fluorescence and phototoxicity of PVP-Hypericin in the A549 cancer cells are compared with those of HLF normal cells. Although, PVP-Hypericin accumulates more in A549 cancer cells, the results show that HLF cells produce dose-dependent photoreactions in the presence of photosensitizer. PVP-Hypericin induces the most optimized anticancer efficacy with moderate side-effects for I(*)=14.27 mW/cm(2) and L=131 ms.
authors.affiliation: University of Vienna, Faculty of Physics, Physics of Physiological Processes, Boltzmanng. 5, A-1090 Vienna, Austria; Hasselt University, Biomedical Research Institute, Agoralaan Building C, 3590 Diepenbeek, Belgium. Electronic address: rozhin.penjweini@uhasselt.be.
authors.forename: Rozhin
authors.initials: R
authors.lastname: Penjweini
authors.forename: Hans G
authors.initials: HG
authors.lastname: Loew
authors.forename: Paul
authors.initials: P
authors.lastname: Breit
authors.forename: Karl W
authors.initials: KW
authors.lastname: Kratky
mesh_terms: D000622:Aminolevulinic Acid / Q000008:administration & dosage*; D000873:Anthracenes; D000970:Antineoplastic Agents / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects* / Q000528:radiation effects*; D045744:Cell Line, Tumor; D003116:Color; D004307:Dose-Response Relationship, Radiation; D004337:Drug Carriers / Q000737:chemistry; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010569:Perylene / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage; D011205:Povidone / Q000737:chemistry*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000873:Anthracenes; D000970:Antineoplastic Agents; D004337:Drug Carriers; D017319:Photosensitizing Agents; D010569:Perylene; C004965:hypericin; D000622:Aminolevulinic Acid; D011205:Povidone
keywords: A549 cancer cells; HLF normal cells; PVP-Hypericin; Side-effects